HIGHLIGHTS
- who: Ying Zhang et al. from the The Chinese University of Hong Kong, Hong Kong SAR, China have published the paper: Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma, in the Journal: (JOURNAL)
- what: In the analysis , the authors first found the possibility that G28.5 in combination with ipilimumab might increase the antitumor efficacy of DC-CIK cells compared to G28.5 or ipilimumab alone, primarily by reducing inhibitory CTLA-4 signaling and proliferating CD3+CD56+ effector cells.
- how: The . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.